TL;DR: Guardian Bio is a Y Combinator Summer 2022 startup Dendritic cell-based platform for cancer therapy , currently active with a team of 2.
Dendritic cell-based platform for cancer therapy
Last verified:
Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic d…
Built by LemStudio
Yes. Guardian Bio was funded by Y Combinator in the Summer 2022 batch. Dendritic cell-based platform for cancer therapy
Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patient…
Guardian Bio was part of Y Combinator's Summer 2022 batch.
Guardian Bio has a team of 2 people according to Y Combinator's directory.
Guardian Bio is currently listed as Active with a team of 2 in Y Combinator's directory.
Loading interactive view…